Cancer immunotherapy in clinical practice -- the past, present, and future.

Chin J Cancer · 2014 · PMC4190434 · PMID 25189717

Europe PMC DOI

hedged sentence

0.0510

closest p · 1.0× alpha

0.0510

boldest claim

The sentences

a strong trendP = 0.051so close (0.05 < p ≤ 0.1)

2%, P < 0.001), with a strong trend toward improved OS in patients treated with T-VEC (23.3 vs. 18.9 months, P = 0.051).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.